Wednesday, February 16, 2011

As Genzyme and Sanofi marry, BioMarin looks at big dowry

The long courtship between Sanofi-Aventis SA and Genzyme Corp. may result in a nice dowry for BioMarin Pharmaceutical Inc.
Novato-based BioMarin (NASDAQ: BMRN) is involved because it makes Aldurazyme, a drug designed to treat a rare, inherited metabolic condition called MPS I. Genzyme sells the drug, with BioMarin receiving royalties of 39.5 percent to 50 percent.

No comments:

Post a Comment